Tonix Pharmaceuticals announced that preclinical results of mTNX-1700 were presented in a poster at the Keystone Symposia, "Cancer Immunotherapy: Mechanisms of Response Versus Resistance" on March 6, 2023, at the Fairmont Banff Springs Conference Center in Banff, Alberta, Canada. The poster, titled "TFF2-MSA Suppresses Tumor Growth and Increases Survival in an anti-PD-1 Treated MC38 Colorectal Cancer Model by Targeting MDSCs," includes data from preclinical studies which evaluated the ability of mTNX-1700 to treat colorectal cancer as monotherapy or in combination with anti-PD-1 in mouse models. TNX-1700 targets myeloid-derived suppressor cells which interfere with the immune response to cancer by suppressing the CD8+ T cell response and creating a toxic tumor microenvironment. The data show that mTNX-1700 and anti-PD-1 monotherapy each were able to evoke anti-tumor immunity in the MC38 model of colorectal cancer, and that mTNX-1700 augmented the anti-tumor efficacy of anti-PD-1 therapy in two different colorectal cancer models. "Anti-PD-1 treatment has revolutionized the treatment of other cancers and is known as immuno-oncology," said Seth Lederman, M.D., Chief Executive Officer of Tonix. "Colorectal cancer is notoriously unresponsive to anti-PD-1 treatment. Much research has been focused on trying to turn anti-PD-1 unresponsive tumors into anti-PD-1 responsive tumors."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TNXP:
- Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell
- Tonix Pharmaceuticals announces virtual event on infections, TNX-102
- Tonix Pharmaceuticals to participate in event on Long COVID
- Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies
- Tonix Pharmaceuticals annunces exclusive license of Anti-SARS-CoV-2 mAbs